Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Recent Patents on Anti-Cancer Drug Discovery
  4. Volume 20, Issue 1
  5. Article
Volume 20, Issue 1
  • ISSN: 1574-8928
  • E-ISSN: 2212-3970

Abstract

Introduction

Splenic marginal zone Lymphoma (SMZL) is a rare, chronic B lymphocyte proliferative disease. Generally, SMZL is accompanied by circulating atypical villous lymphocytes, known as SMZL with villous lymphocytes. Rituximab is a chimeric monoclonal antibody to CD20; recent but limited studies have confirmed its effectiveness in treating SMZL. Given the low incidence and selection of treatment, statistical comparisons of rituximab monotherapy with other available treatment options with the full range of data from previous clinical studies remain sparse. Here, we report a case of SMZL with villous lymphocytes treated by rituximab monotherapy, which is especially infrequently reported.

Case Report

A 63-year-old Chinese female was presented to the hospital with complaints of splenomegaly and pain in the spleen area. Immunohistochemistry analysis was positive for IGH, IGK, and IGL clonal rearrangement. Villous lymphocytes were found in peripheral blood and bone marrow, along with further immunotyping results. The case was considered as SMZL with villous lymphocytes. Based on the SMZLSG prognosis assessment, we applied rituximab monotherapy. After eight cycles of rituximab treatment, the patient’s condition improved markedly, with blood constituent and size of the spleen returning to normal levels, achieving complete response, with no significant side effect observed.

Discussion

The patient provides a typical SMZL with villous lymphocytes case treated with rituximab monotherapy. Currently, the main treatment options include splenectomy and rituximab. After synthesizing a series of current views, we put forward our opinion about the selection of therapy for SMZL patients in order to gain maximum benefits for patients in need of treatment.

Conclusion

Our analysis found no statistically significant difference between rituximab monotherapy and rituximab combined with chemotherapy, while rituximab treatments resulted in better therapeutic effects than chemotherapy. Rituximab monotherapy has favorable therapeutic effects and minor adverse effects (AEs) in treating SMZL.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/pra/10.2174/0115748928247369231024112003
2023-11-03
2025-01-01

  • From This Site

    /content/journals/pra/10.2174/0115748928247369231024112003
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ArcainiL. RossiD. PaulliM. Splenic marginal zone lymphoma: From genetics to management.Blood2016127172072208110.1182/blood‑2015‑11‑624312 26989207
     [Google Scholar]
  2. LiuL. WangH. ChenY. RustveldL. LiuG. DuX.L. Splenic marginal zone lymphoma: A population-based study on the 2001–2008 incidence and survival in the United States.Leuk. Lymphoma20135471380138610.3109/10428194.2012.743655 23101590
     [Google Scholar]
  3. FlorindezJ.A. AlderuccioJ.P. ReisI.M. LossosI.S. Splenic marginal zone lymphoma: A US population‐based survival analysis (1999‐2016).Cancer2020126214706471610.1002/cncr.33117 32767702
     [Google Scholar]
  4. SabattiniE. BacciF. SagramosoC. PileriS.A. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: An overview.Pathologica201010238387 21171509
     [Google Scholar]
  5. MatutesE. OscierD. MontalbanC. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria.Leukemia200822348749510.1038/sj.leu.2405068 18094718
     [Google Scholar]
  6. TarellaC. ArcainiL. BaldiniL. Italian society of hematology, italian society of experimental hematology, and italian group for bone marrow transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma).Clin. Lymphoma Myeloma Leuk.2015152758510.1016/j.clml.2014.07.002 25108679
     [Google Scholar]
  7. LengletJ. TraulléC. MounierN. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment.Leuk. Lymphoma20145581854186010.3109/10428194.2013.861067 24206091
     [Google Scholar]
  8. IannittoE. MinardiV. CalvarusoG. Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes.Eur. J. Haematol.200575213013510.1111/j.1600‑0609.2005.00426.x 16000129
     [Google Scholar]
  9. LefrèreF. LévyV. FrançoisS. Fludarabine therapy in patients with splenic lymphoma with villous lymphocytes: An update.Leukemia200418111924192510.1038/sj.leu.2403440 15385943
     [Google Scholar]
  10. RiccioniR. CaraccioloF. GalimbertiS. CecconiN. PetriniM. Low dose 2-CdA schedule activity in splenic marginal zone lymphomas.Hematol. Oncol.200321416316810.1002/hon.717 14735554
     [Google Scholar]
  11. KalpadakisC. PangalisG.A. DimopoulouM.N. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma.Hematol. Oncol.200725312713110.1002/hon.820 17514771
     [Google Scholar]
  12. BennettM. YegenaS. DaveH.P. SchechterG.P. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma.Hematol. Oncol.200826211410.1002/hon.844 18271062
     [Google Scholar]
  13. IannittoE. LuminariS. TripodoC. Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: A Fondazione Italiana Linfomi phase II study.Leuk. Lymphoma201556123281328710.3109/10428194.2015.1029925 25791121
     [Google Scholar]
  14. ZhangS. XuanZ. ZhangL. LuJ. SongP. ZhengS. Splenic marginal zone lymphoma: A case report and literature review.World J. Surg. Oncol.202018125910.1186/s12957‑020‑02030‑3 33004051
     [Google Scholar]
  15. MontalbánC. AbrairaV. ArcainiL. Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: Development and validation on 593 cases.Br. J. Haematol.2012159216417110.1111/bjh.12011 22924582
     [Google Scholar]
  16. TsimberidouA.M. CatovskyD. SchletteE. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.Cancer2006107112513510.1002/cncr.21931 16700034
     [Google Scholar]
  17. BennettM. SharmaK. YegenaS. GavishI. DaveH.P. SchechterG.P. Rituximab monotherapy for splenic marginal zone lymphoma.Haematologica2005906856858 15951303
     [Google Scholar]
  18. SallesG. BarrettM. FoàR. Rituximab in B-Cell hematologic malignancies: A review of 20 years of clinical experience.Adv. Ther.201734102232227310.1007/s12325‑017‑0612‑x 28983798
     [Google Scholar]
  19. BanchereauJ. RoussetF. Human B lymphocytes: Phenotype, proliferation, and differentiation.Adv. Immunol.19925212526210.1016/S0065‑2776(08)60876‑7 1442306
     [Google Scholar]
  20. a BorossP. LeusenJ.H. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans.Nature200643970778851855
     [Google Scholar]
  21. b WengW.K. LevyR. ImmunoglobulinG. Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma.Leuk. Lymphoma200950914941500 19672774
     [Google Scholar]
  22. KalpadakisC. PangalisG.A. AngelopoulouM.K. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: Progress report and comparison with splenectomy.Oncologist201318219019710.1634/theoncologist.2012‑0251 23345547
     [Google Scholar]
  23. ElseM. Marín-NieblaA. de la CruzF. Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma.Br. J. Haematol.2012159332232810.1111/bjh.12036 23016878
     [Google Scholar]
  24. DreylingM. ThieblemontC. GallaminiA. ESMO Consensus conferences: Guidelines on malignant lymphoma. part 2: Marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.Ann. Oncol.201324485787710.1093/annonc/mds643 23425945
     [Google Scholar]
  25. KalpadakisC. PangalisG.A. SachanasS. No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab.Leuk. Lymphoma201657112705270810.3109/10428194.2016.1157877 27082039
     [Google Scholar]
  26. KalpadakisC. PangalisG.A. AngelopoulouM.K. VassilakopoulosT.P. Treatment of splenic marginal zone lymphoma.Best Pract. Res. Clin. Haematol.2017301-213914810.1016/j.beha.2016.07.004 28288709
     [Google Scholar]
  27. XingK.H. KahlonA. SkinniderB.F. Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia.Br. J. Haematol.2015169452052710.1111/bjh.13320 25854936
     [Google Scholar]
  28. PozzatoG. MazzaroC. CrovattoM. Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia.Blood19948493047305310.1182/blood.V84.9.3047.3047 7949176
     [Google Scholar]
  29. HermineO. LefrèreF. BronowickiJ.P. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection.N. Engl. J. Med.20023472899410.1056/NEJMoa013376 12110736
     [Google Scholar]
  30. IannittoE. AmbrosettiA. AmmatunaE. Splenic marginal zone lymphoma with or without villous lymphocytes.Cancer200410192050205710.1002/cncr.20596 15389479
     [Google Scholar]
  31. ThieblemontC. FelmanP. BergerF. Treatment of splenic marginal zone B-cell lymphoma: An analysis of 81 patients.Clin. Lymphoma200231414710.3816/CLM.2002.n.010 12141954
     [Google Scholar]
  32. LefrÈRe F, Hermine O, FranÇOis S, et al. Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes.Leuk. Lymphoma2000401-211311710.3109/10428190009054887 11426611
     [Google Scholar]
  33. OrciuoloE. BudaG. SordiE. 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma.Leuk. Res.201034218418910.1016/j.leukres.2009.04.003 19414190
     [Google Scholar]
  34. LefrèreF. HermineO. BelangerC. Fludarabine: An effective treatment in patients with splenic lymphoma with villous lymphocytes.Leukemia200014457357510.1038/sj.leu.2401710 10764141
     [Google Scholar]
  35. CervettiG. GalimbertiS. PelosiniM. GhioF. CecconiN. PetriniM. Significant efficacy of 2-chlorodeoxyadenosine± rituximab in the treatment of splenic marginal zone lymphoma (SMZL): Extended follow-up.Ann. Oncol.20132492434243810.1093/annonc/mdt181 23712547
     [Google Scholar]
  36. ChacónJ.I. MollejoM. MuñozE. Splenic marginal zone lymphoma: Clinical characteristics and prognostic factors in a series of 60 patients.Blood200210051648165410.1182/blood.V100.5.1648.h81702001648_1648_1654 12176884
     [Google Scholar]
  37. MulliganS.P. MatutesE. DeardenC. CatovskyD. Splenic lymphoma with villous lymphocytes: Natural history and response to therapy in 50 cases.Br. J. Haematol.199178220620910.1111/j.1365‑2141.1991.tb04417.x 2064958
     [Google Scholar]
/content/journals/pra/10.2174/0115748928247369231024112003
Loading
Optimal Rituximab Monotherapy in Splenic Marginal Zone Lymphoma (SMZL): A Case Report and Brief Review
Recent Patents on Anti-Cancer Drug Discovery 20, 121 (2025); https://doi.org/10.2174/0115748928247369231024112003
/content/journals/pra/10.2174/0115748928247369231024112003
/content/journals/pra/10.2174/0115748928247369231024112003
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Case Report
Keyword(s): case report; immunotargeted therapy; meta analysis; monotherapy; rituximab; Splenic marginal zone lymphoma

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test